JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia
| Autor: | Margherita Scapin, Elena Duner, Fabiana Tezza, Maria Luigia Randi, Elisabetta Ruzzon, Fabrizio Fabris, Raffaella Scandellari |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Aging medicine.medical_specialty Bone density Osteoporosis Essential thrombocythemia Polycythemia vera medicine JAK2V617F Humans Jak2v617f mutation Medical prescription Intensive care medicine Polycythemia Vera Aged Old patients business.industry Age Factors Janus Kinase 2 Middle Aged medicine.disease Surgery Mutation Orthopedic surgery Female Geriatrics and Gerontology business Thrombocythemia Essential |
| Zdroj: | Aging Clinical and Experimental Research. 23:17-21 |
| ISSN: | 1720-8319 1594-0667 |
| Popis: | JAK2V617F mutation occurs in 90% of polycythemia vera (PV) and in 50% of essential thrombocythemia (ET) patients.253 consecutive patients affected by myeloproliferative disorders (MPD, 121 PV, 132 ET) were evaluated and stratified in 4 age groups: 18-39, 40-59, 60-75 and over 75 years (75). The JAK2V617F mutation was searched and its allele burden was evaluated.The percentage of mutated patients increased progressively with age mainly in patients75 (p=0.0015 vs 18-39, p=0.0021 vs 40-59 and p=0.012 vs 60-75). We also found a progressive increase in allele burden with age (R2=0.042). Thrombotic events were more common in patients carrying the mutation in comparison with wild type (WT) (p=0.006, coefficient risk 1.94). No differences in the percentage of patients carrying the JAK2V617F mutation were found, in spite of different follow-up durations (5 yrs, 5-10 yrs, 10-15 yrs,15 yrs). The JAK2V617F allele burden was similar in patients with (57 ± 31%) and without (45 ± 26%) long-term hydroxyurea treatment.JAK2V617F mutation is more common in old than in young patients with MPD. Older patients have an higher allele burden. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink